Agents and Actions

, Volume 12, Issue 5, pp 700–701 | Cite as

Platelet-activating factor (PAF-acether): Historical background and definition

  • J. Benveniste
Platelets and Thrombosis

Abstract

The platelet-activating factor (PAF-acether) was first described as released from sensitized basophils. It is now recognized as a mediator of inflammation, since it is released from most stimulated pro-inflammatory cells. It has a unique phospholipid structure and, as yet, is the most potent platelet-activating agent acting at the 1×10−12 to 1×10−10M level. It also degranulates and attracts neutrophils. Its release from alveolar macrophages might play a role in the onset of bronchoconstriction in experimental animals and in man. Thus, PAF-acether is gaining increasing importance as a major intermediate of inflammatory reactions.

Keywords

Experimental Animal Inflammatory Reaction Alveolar Macrophage Historical Background Major Intermediate 

References

  1. [1]
    J.F. Barbaro andN.J. Zvaifler, Proc. Soc. exp. Biol. Med.122, 1245–1247 (1966).PubMedGoogle Scholar
  2. [2]
    R.P. Siraganian andA.G. Osler, J. Immun.106, 1244–1251 (1971).PubMedGoogle Scholar
  3. [3]
    J. Benveniste, P.M. Henson andC.G. Cochrane, J. exp. Med.136, 1356–1377 (1972).Google Scholar
  4. [4]
    J. Benveniste, Nature, Lond.249, 581–582 (1974).Google Scholar
  5. [5]
    J. Benveniste, J.P., Le Couedic andP. Kamoun, LancetI, 344 (1975).CrossRefGoogle Scholar
  6. [6]
    M.C. O'Donnell, P.M. Henson andB.A. Fiedel, Immunology35, 953–958.Google Scholar
  7. [7]
    J. Benveniste, J.P. Le Couedic, J. Polonsky andM. Tence, Nature, Lond.269, 170–171 (1977).Google Scholar
  8. [8]
    C.A. Demopoulos, R.N. Pinckard andD.J. Hanahan, J. biol. Chem.354, 9355–9358 (1979).Google Scholar
  9. [9]
    J. Benveniste, M. Tence, P. Varenne, J. Bidault, C. Boullet andJ. Polonsky, C. r. hebd. Séanc. Acad. Sci., Paris289D, 1037–1040 (1979).Google Scholar
  10. [10]
    J.J. Goldfroid, F. Heymans, E. Michel, H.C. Redeuilh, E. Steiner andJ. Benveniste, FEBS Lett.116, 161–164 (1980).CrossRefPubMedGoogle Scholar
  11. [11]
    F. Heymans, E. Michel, M.C. Borrel, B. Wichrowski, J.J. Godfroid, O. Convert, E. Coeffier, M. Tencé andJ. Benveniste, Biochim. biophys. Acta666, 230–237 (1981).PubMedGoogle Scholar
  12. [12]
    D.J. Hanahan, C.A. Demopoulos, J. Liehr andR.N. Pinckard, J. biol. Chem.255, 5514–5516 (1980).PubMedGoogle Scholar
  13. [13]
    E.J. Goetzl, C.K. Derian, A.I. Tauber andF.H. Valone, Biochem. biophys. Res. Commun.94, 881–888 (1980).CrossRefPubMedGoogle Scholar
  14. [14]
    M. Tence, E. Coeffier, F. Heymans, J. Polonsky, J.J. Godfroid andJ. Benveniste, Biochimie63, 723–727 (1981).PubMedGoogle Scholar
  15. [15]
    G. Camussi, C. Tetta, F. Bussolino, F. Caligaris Cappio, R. Coda, C. Masera andG. Segoloni, Int. Archs Allergy appl Immun.64, 24–41 (1981).Google Scholar
  16. [16]
    J.T. O'Flaherty, R.L. Wykle, C.H. Miller, J.C. Lewis, M. Waite, A. Bass, C.E. McCall andL.R. Dechatelet, Am. J. Pathol.103, 70–79 (1981).PubMedGoogle Scholar
  17. [17]
    E. Jouvin-Marche, B. Poitevin andJ. Benveniste, Agents and Actions, this issue.Google Scholar
  18. [18]
    B.B. Vargafitg, J. Lefort, M. Chignard andJ. Benveniste, Eur. J. Pharmac.65, 185–192 (1980).CrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag 1982

Authors and Affiliations

  • J. Benveniste
    • 1
  1. 1.INSERM U 200ClamartFrance

Personalised recommendations